
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            SC134-deruxtecan, a fucosyl-GM1 targeting ADC for small cell lung cancer therapy - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="AE53411B8AF3CA5305411B001EADB675.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="transmed">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366213/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Journal of Translational Medicine">
<meta name="citation_title" content="SC134-deruxtecan, a fucosyl-GM1 targeting ADC for small cell lung cancer therapy">
<meta name="citation_author" content="Bryony Heath">
<meta name="citation_author_institution" content="Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK">
<meta name="citation_author" content="Bubacarr G Kaira">
<meta name="citation_author_institution" content="Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK">
<meta name="citation_author" content="Dhruma Thakker">
<meta name="citation_author_institution" content="Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK">
<meta name="citation_author" content="Omar J Mohammed">
<meta name="citation_author_institution" content="Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK">
<meta name="citation_author" content="Ruhul Choudhury">
<meta name="citation_author_institution" content="Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK">
<meta name="citation_author" content="Foram Dave">
<meta name="citation_author_institution" content="Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK">
<meta name="citation_author" content="Poonam Vaghela">
<meta name="citation_author_institution" content="Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK">
<meta name="citation_author" content="Elena Dubinina">
<meta name="citation_author_institution" content="Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK">
<meta name="citation_author" content="Tina Parsons">
<meta name="citation_author_institution" content="Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK">
<meta name="citation_author" content="Lindy Durrant">
<meta name="citation_author_institution" content="Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK">
<meta name="citation_author_institution" content="Scancell Ltd., Bellhouse Building, Oxford Science Park, Oxford, UK">
<meta name="citation_author" content="Mireille Vankemmelbeke">
<meta name="citation_author_institution" content="Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK">
<meta name="citation_publication_date" content="2025 Aug 19">
<meta name="citation_volume" content="23">
<meta name="citation_firstpage" content="940">
<meta name="citation_doi" content="10.1186/s12967-025-06940-2">
<meta name="citation_pmid" content="40830881">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366213/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366213/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366213/pdf/12967_2025_Article_6940.pdf">
<meta name="description" content="Small cell lung cancer (SCLC) remains a difficult disease to treat with poor long-term survival rates. New therapies offer modest overall survival benefit beyond that of chemotherapy alone, necessitating the development of improved therapies. ...">
<meta name="og:title" content="SC134-deruxtecan, a fucosyl-GM1 targeting ADC for small cell lung cancer therapy">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Small cell lung cancer (SCLC) remains a difficult disease to treat with poor long-term survival rates. New therapies offer modest overall survival benefit beyond that of chemotherapy alone, necessitating the development of improved therapies. ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366213/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12366213">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s12967-025-06940-2"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/12967_2025_Article_6940.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12366213%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12366213/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12366213/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366213/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-transmed.png" alt="Journal of Translational Medicine logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Journal of Translational Medicine" title="Link to Journal of Translational Medicine" shape="default" href="https://translational-medicine.biomedcentral.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">J Transl Med</button></div>. 2025 Aug 19;23:940. doi: <a href="https://doi.org/10.1186/s12967-025-06940-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s12967-025-06940-2</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22J%20Transl%20Med%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22J%20Transl%20Med%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J%20Transl%20Med%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22J%20Transl%20Med%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>SC134-deruxtecan, a fucosyl-GM1 targeting ADC for small cell lung cancer therapy</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Heath%20B%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Bryony Heath</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Bryony Heath</span></h3>
<div class="p">
<sup>1</sup>Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Heath%20B%22%5BAuthor%5D" class="usa-link"><span class="name western">Bryony Heath</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kaira%20BG%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Bubacarr G Kaira</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Bubacarr G Kaira</span></h3>
<div class="p">
<sup>1</sup>Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kaira%20BG%22%5BAuthor%5D" class="usa-link"><span class="name western">Bubacarr G Kaira</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Thakker%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Dhruma Thakker</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Dhruma Thakker</span></h3>
<div class="p">
<sup>1</sup>Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Thakker%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Dhruma Thakker</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mohammed%20OJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Omar J Mohammed</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Omar J Mohammed</span></h3>
<div class="p">
<sup>1</sup>Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mohammed%20OJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Omar J Mohammed</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Choudhury%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Ruhul Choudhury</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Ruhul Choudhury</span></h3>
<div class="p">
<sup>1</sup>Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Choudhury%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Ruhul Choudhury</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dave%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Foram Dave</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Foram Dave</span></h3>
<div class="p">
<sup>1</sup>Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dave%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Foram Dave</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vaghela%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Poonam Vaghela</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Poonam Vaghela</span></h3>
<div class="p">
<sup>1</sup>Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vaghela%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Poonam Vaghela</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dubinina%20E%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Elena Dubinina</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Elena Dubinina</span></h3>
<div class="p">
<sup>1</sup>Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dubinina%20E%22%5BAuthor%5D" class="usa-link"><span class="name western">Elena Dubinina</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Parsons%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Tina Parsons</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Tina Parsons</span></h3>
<div class="p">
<sup>1</sup>Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Parsons%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Tina Parsons</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Durrant%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Lindy Durrant</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Lindy Durrant</span></h3>
<div class="p">
<sup>1</sup>Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK </div>
<div class="p">
<sup>2</sup>Scancell Ltd., Bellhouse Building, Oxford Science Park, Oxford, UK </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Durrant%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Lindy Durrant</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vankemmelbeke%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Mireille Vankemmelbeke</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Mireille Vankemmelbeke</span></h3>
<div class="p">
<sup>1</sup>Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vankemmelbeke%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mireille Vankemmelbeke</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK </div>
<div id="Aff2">
<sup>2</sup>Scancell Ltd., Bellhouse Building, Oxford Science Park, Oxford, UK </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Jun 13; Accepted 2025 Jul 24; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12366213  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40830881/" class="usa-link">40830881</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background</h3>
<p id="Par1">Small cell lung cancer (SCLC) remains a difficult disease to treat with poor long-term survival rates. New therapies offer modest overall survival benefit beyond that of chemotherapy alone, necessitating the development of improved therapies. Fucosyl-GM1 (FucGM1) is a glycolipid highly expressed on SCLC cells, but virtually absent in normal tissues, suggesting strong potential for targeted therapy. We have developed SC134-deruxtecan, an antibody drug conjugate (ADC) targeting FucGM1 in SCLC, and characterized its preclinical activity.</p></section><section id="sec2"><h3 class="pmc_sec_title">Methods</h3>
<p id="Par2">SC134 binding specificity and affinity were tested through enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), flow cytometry against several SCLC cell lines, and immunohistochemistry (IHC) of clinical samples and animal tissues. In silico modelling supplemented the FucGM1 binding specificity. Internalization kinetics and colocalization of SC134 with the lysosomes were investigated through imaging flow cytometry. Direct cytotoxicity as well as bystander killing and antibody dependent cell cytotoxicity (ADCC) by SC134-deruxtecan were determined using in vitro cell cytotoxicity assays. SC134-deruxtecan’s efficacy was evaluated in vivo using a DMS79 xenograft model.</p></section><section id="sec3"><h3 class="pmc_sec_title">Results</h3>
<p id="Par3">SC134 specifically targets FucGM1, without GM1 cross-reactivity, with nanomolar affinity. In silico modelling of the SC134 FucGM1 binding site revealed a relatively narrow binding pocket, occupied by the terminal three glycans with multiple Fucose-engaging interactions. Robust FucGM1 expression in frozen SCLC patient tissues was evident, whilst tissue cross-reactivity analysis indicated non-human primates as well as mice as suitable tox models. FucGM1 binding by SC134 led to effective internalization, with a 6.9-h half-life, lysosomal colocalization, culminating in sub-nanomolar drug delivery efficiency, across a range of payloads. Covalent deruxtecan conjugation of SC134 with a DAR 8 and a cleavable linker showed effective (nanomolar) in vitro killing of SCLC cell lines such as DMS79 and DMS153, with concentration-dependent bystander killing of FucGM1-negative AGS cells. SCLC cell killing was further augmented through ADCC. Potent i<em>n vivo</em> DMS79 xenograft killing was seen at 3mg/kg SC134-deruxtecan, which was well tolerated.</p></section><section id="sec4"><h3 class="pmc_sec_title">Conclusion</h3>
<p id="Par4">The tumour-specific nature of FucGM1, combined with the potent SCLC killing by SC134-deruxtecan underscore the development potential of SC134 for use as an ADC therapy against SCLC.</p></section><section id="sec5"><h3 class="pmc_sec_title">Supplementary Information</h3>
<p>The online version contains supplementary material available at 10.1186/s12967-025-06940-2.</p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Fucosyl-GM1, Glycolipid, Internalization, ADC, Small cell lung cancer</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Background</h2>
<p id="Par62">Lung cancer is the second most common cancer and is the leading cause of cancer death in both men and women [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>]. Small cell lung cancer (SCLC), constituting up to 15% of all lung cancers, is an aggressive disease with poor prognosis. At the limited stage (LS-SCLC), surgery followed by chemo/radiotherapy, with or without immunotherapy, can be effective. The majority of patients, however, present at the disseminated (extensive) stage (ES-SCLC), where etoposide plus platinum-based chemotherapy with or without radiotherapy (standard of care, SOC) initially shows good impact, but patients soon progress. In recent years, the addition of immunotherapy (PD-L1 inhibitors) in the first line (1L) setting has shown further modest improvements (2–3 months overall survival (OS) improvement), but patients still progress whilst on maintenance immunotherapy [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>–<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>]. A number of second line (2L) options are available such as Topotecan, Lubirnectin, or checkpoint inhibitors, but the 5-year survival rates remain extremely low, underscoring the need for additional treatments [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>].</p>
<p id="Par63">Glycosphingolipids are abundant in the outer leaflet of the plasma membrane, where they impact on membrane protein function, through microdomain formation or lateral association [<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>, <a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>]. Dramatic changes in membrane glycosphingolipid composition occur during normal development and malignant transformation [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>, <a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>]. More recently, functional genomics screening revealed an essential role for membrane sphingolipids in enabling tumour growth in immunocompetent mice, highlighting their importance in immune evasion [<a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>]. Fucosyl GM1 (FucGM1) is a ganglioside originally discovered as being highly expressed by SCLC samples [<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>, <a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>]. In these early reports, FucGM1 expression was shown to be specifically associated with both primary and metastasised samples from SCLC patients with extremely limited expression on normal tissues [<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>]. FucGM1 is a monosialoganglioside composed of a ceramide lipid tail which inserts into the membrane and a surface exposed oligosaccharide headgroup comprising Fucα1-2Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glc (Fig. <a href="#Fig1" class="usa-link">1</a>A) [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>]. GM1, the precursor to FucGM1, is expressed in the nervous system where it plays a role in the maturation and maintenance of neuronal tissues [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]. The <em>α</em>(1,2)-fucosyltransferase genes, <em>Fut1</em> and <em>Fut2</em>, are responsible for fucosylation of FucGM1 in a species and tissue-specific manner [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>, <a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>]. Analysis of a panel of SCLC cell lines, however revealed frequent inactivating <em>Fut2</em> mutations that did not impact on the FucGM1 surface expression, indicating that <em>Fut1</em> is likely the key driver for FucGM1 expression in SCLC. Additionally, a role for <em>Fut1 in</em> maintaining pluripotency during embryonic development has also recently been established [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>].</p>
<figure class="fig xbox font-sm" id="Fig1"><h3 class="obj_head">Fig. 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366213_12967_2025_6940_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1cf/12366213/7469969d6545/12967_2025_6940_Fig1_HTML.jpg" loading="lazy" id="MO1" height="587" width="724" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>SC134 exhibits avid FucGM1 binding, facilitated by a narrow binding pocket <strong>A</strong> FucGM1 cartoon with sphingosine and hydrophobic lipid tail, the importance of the Fucose residue in binding is highlighted; <strong>B</strong> ELISA binding of FucGM1 (ceramide and BSA conjugate) to SC134, absence of GM1 cross reactivity; <strong>C</strong> Biacore analysis of real-time SC134 binding to FucGM1-BSA compared to GM1a-BSA); <strong>D</strong> In silico modelling of FucGM1 glycolipid binding to SC134</p></figcaption></figure><p id="Par64">FucGM1 has been pursued as an immunotherapy target in a range of settings. Dickler et al. trialled vaccination using FuGM1-linked KLH in the adjuvant setting, with most patients mounting a FucGM1-specific serological response [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>]. More recently, BMS-986012, optimised for effector function and showing encouraging preclinical efficacy, has progressed to PhII/III in combination with checkpoint inhibition [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>, <a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>], supporting the notion that FucGM1 is an effective target for SCLC therapy and paving the way for other FucGM1-targeting modalities to be evaluated. We recently described a FucGM1-targeting T cell engaging bispecific, SC134-TCB, showing potent ex vivo and in vivo SCLC tumour cell killing [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. Additionally, antibody drug conjugates (ADC) continue to show great promise in solid tumour settings. Here we present results on the FucGM1-targeting SC134-ADC, comprising the humanised SC134 antibody conjugated to the topoisomerase 1 inhibitor (TOP1i), deruxtecan, showing encouraging preclinical in vitro and in vivo efficacy. Importantly, we provide a structural model for selective FucGM1 binding by SC134, as well as FucGM1 target distribution in SCLC patient tissues.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Methods</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Materials, cells, and antibodies</h3>
<p id="Par65">DMS79, DMS153, DMS53, H526, and AGS cells were obtained from American Type Culture Collection (ATCC) and maintained at low passage number. DMS79 and H526 cells were cultured in RPMI 1640 (Sigma), supplemented with 10% FBS (Sigma). AGS cells were cultured in Kaighn’s Modification of Ham’s F-12 Medium (F12-K) (ATCC), supplemented with 10% FBS. DMS153 and DMS53 cells were cultured in Waymouth’s medium (Gibco), supplemented with 10% FBS. Cell lines were tested monthly for the presence of mycoplasma and were maintained at low passage number for experiments.</p></section><section id="Sec4"><h3 class="pmc_sec_title">Generation of SC134</h3>
<p id="Par66">Hybridoma 134 was created via BALB/c mice immunizations with a complex immunisation regimen [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. The hybridoma-derived antibody, a murine (m) IgG1 with κ light chain, was subsequently chimerized (huIgG1), followed by humanisation using Composite Human Antibody™ Technology (Abzena) to generate SC134.</p></section><section id="Sec5"><h3 class="pmc_sec_title">Target binding analysis via ELISA</h3>
<p id="Par67">ELISA plates were coated with 200 ng/well FucGM1 or GM1 ceramide (both Matreya LLC) or FucGM1-BSA (Elicityl) followed by blocking with 2% BSA-PBS. Primary antibody dilutions were detected using anti–human IgG (<em>γ</em>-chain specific)–biotin antibody (Sigma), followed by streptavidin–HRP conjugate.</p></section><section id="Sec6"><h3 class="pmc_sec_title">Indirect immunofluorescence and flow cytometry</h3>
<p id="Par68">SC134 cell binding was analysed by flow cytometry. Briefly, 1 × 10<sup>5</sup> SCLC cells were incubated with serially diluted SC134 for 1 h at 4 °C. Following washing, bound SC134 was detected using FITC-labelled anti-human IgG Fc (Sigma). Stained samples were washed and resuspended in IC Fixation buffer (Invitrogen) followed by analysis on a MACSQuant 16 flow cytometer, equipped with MACSQuant software version 2.13.3. EC50 values were determined via three parameter non-linear regression. The number of antibody binding sites was determined using QIFIKIT (Agilent), according to the manufacturer’s protocol. Specific antibody binding capacity (SABC) was deduced by interpolation onto the calibration curve using Graphpad Prism v10.2.3.</p></section><section id="Sec7"><h3 class="pmc_sec_title">Kinetic internalization</h3>
<p id="Par69">Imaging flow cytometry was carried out to determine antibody internalization. Briefly, 100,000 DMS79 cells were incubated with Alexa Fluor 647 (AF647) labelled SC134 on ice for 1 h. Cells were washed with ice cold FACS medium, before being span down at 300 g for 5 min at 4 °C. Cells were cultured in their respective culture medium for 0, 1, 3, 6, 24, and 48 h. For the final 10 min of incubation Live/Dead yellow (Thermo Fisher) viability dye was added at a 1:50 dilution before being washed with ice cold FACS medium, span down at 300 g for 5 min, at 4 °C, and resuspended in IC fixation buffer. The samples were processed on an ImageStreamX MkII imaging flow cytometer and data was interpreted using IDEAS software, version 6.2. The software was used to give an internalization score for viable DMS79 cells which is determined as the ratio of internal fluorescence over total fluorescence, on a log scale. Positive internalization scores represent a population with a majority of internal fluorescence, negative scores represent a population with a majority of external (membrane-bound) fluorescence, and a score of 0 represents a population with equal levels of internal and external fluorescence. The half-life for internalization was calculated using the formulae ln(2)/K, where K is the rate constant.</p></section><section id="Sec8"><h3 class="pmc_sec_title">Lysosomal colocalization</h3>
<p id="Par70">Imaging flow cytometry was used to determine the degree of colocalization between the lysosomal marker LAMP1 and internalized SC134-AF647. Briefly, 4 × 10<sup>6</sup> DMS79 cells were incubated with Alexa Fluor 647 labelled SC134 on ice for 1 h. Following incubation, cells were washed with ice cold FACS medium. 500,000 labelled cells were added per well in a 24-well plate in complete medium and incubated for 0, 1, 3, 5.5, 24, and 48 h at 37 °C, 5% CO<sub>2</sub>. For the final 10 min of incubation Live/Dead yellow (Thermo Fisher) viability dye was added at a 1:50 dilution. Following incubation, cells were washed with ice cold FACS and fixed using IC Fixation buffer for 20 min. Following fixation, cells were permeabilised using permeabilization buffer (Invitrogen) and labelled with anti-LAMP1-AF488 (Cell Signalling Technology). Following an incubation of 30 min, cells were washed and resuspended in IC Fixation buffer. The samples were processed on an ImageStreamX MkII imaging flow cytometer and data was interpreted using IDEAS software, version 6.2. The bright detail similarity feature was used to determine the degree of colocalization between AF647 and AF488 fluorescence, and Live/Dead yellow dye was used to exclude dead cells from the analysis.</p></section><section id="Sec9"><h3 class="pmc_sec_title">Kinetic binding analysis Biacore T200</h3>
<p id="Par71">The kinetics parameters for SC134 binding to immobilised FucGM1-BSA, used as a surrogate for the FucGM1 glycolipid, was determined by Surface Plasmon resonance (SPR, Biacoare™ T200, Cytiva). Covalent immobilisation of FucGM1-BSA (immobilised density, 178.6RU) or GM1a-BSA (immobilised density, 132.9RU, both from Elicityl) was achieved using a CM5 chip, with an HSA-coated flow cell used as a reference cell. For kinetics analysis, SC134 binding to FucGM1-BSA or GM1a-BSA was monitored by flowing SC134 across the coated surfaces at increasing concentration (1.56–50 nmol/L) using the multi-cycle kinetics (MCK) option and regeneration with 10 mM Glycine pH 1.5. Data processing and analysis were performed using Biacore T200 evaluation software V 2.0.1. All sensorgrams from the analysis were double referenced.</p></section><section id="Sec10"><h3 class="pmc_sec_title">In silico structural modelling (Phyre2.2 and HADDOCK)</h3>
<p id="Par72">Homology modelling (Phyre2.2) using PSI-blast was used to create a theoretical SC134 model [<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>]. The top model from the list (PDB 2GHW, <em>crystal structure of SARS spike protein receptor binding domain in complex with a neutralizing antibody, 80R)</em>, was selected based on the percentage confidence and coverage. The coordinates for the 3D structural homology model were saved as a PDB, after deletion of hetero atoms and water molecules, followed by model validation using MolProbidity. The coordinate file for FucGM1 was obtained from RCSB Protein Data Bank (PDB 6HMY: C<em>rystal structure of Cholera toxin classical B-pentamer in complex with FucGM1</em>). PDB files for SC134 and FucGM1 were uploaded to the HADDOCK (HADDOCK 2.4) submission interface for molecular docking. Inputs for molecules 1 and 2 were SC134 model and Glycan (FucGM1) respectively. For SC134, all the CDRs were selected as active residues and for FucGM1 all residues except terminal beta-D-Glucopyranose (BGC1) were selected for the docking run. Docking parameters were left on default. From the output data, clusters were generated and within each cluster are 4 models. HADDOCK score, cluster size, z-score and other scoring are generated for each cluster. The top cluster usually considered most reliable were downloaded and analysed in PYMOL to assess SC134 and FucGM1 interactions. Final figures were created using PYMOL and Biorender.</p></section><section id="Sec11"><h3 class="pmc_sec_title">Drug conjugation</h3>
<p id="Par73">Conjugation was carried out by Sterling Pharma Solutions. SC134 and Rituximab were fully reduced to generate eight free thiols for alkylation with Deruxtecan. Deruxtecan was linked via Cathepsin B-cleavable glycine-glycine-phenylalanine-glycine linker. Once manufactured, the ADC was purified by Sephadex G25 exchange into PBS, and residual toxin linker removed via contact with activated carbon. Average Drug to antibody ratio (DAR) was determined through reversed-phase high-performance liquid chromatography (RP-HPLC) (Supplemental Fig. 2).</p></section><section id="Sec12"><h3 class="pmc_sec_title">Immunohistochemistry</h3>
<p id="Par74">Immunohistochemistry was carried out as previously described [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>] using SC134 (10<em>μ</em>g/ml), and Human IgG1 isotype (#31154, Thermofisher Scientific), combined with the human-on-human kit (HOH-3000, Vector Laboratories) according to the manufacturer’s protocol. Where the murine (m) 134 (10 μg/ml) was used, mouse IgG1 isotype (Abcam-ab18443) was included combined with horseradish peroxidase (HRP) labelled goat anti-mouse polymer (MHRP520L, Biocare Medical). Additional markers comprised: Thyroid transcription factor 1 (TTF-1) (Abcam-ab133737) and Delta like ligand-3 (DLL3) (Cell Signalling-71804T) ab with rabbit IgG Isotype (Abcam-ab172730) in combination with goat anti-rabbit polymer and CD56 (Agilent- M730429-2). Frozen tissue sections were air-dried and rehydrated with cold PBS followed by blocking of endogenous peroxidase activity and protein block. Primary antibodies were applied using antibody diluent mixture, followed by the relevant horseradish peroxidase (HRP) labelled polymer and DAB. Hematoxylin-modified Mayer’s solution was used for counterstaining. Slides were dehydrated, mounted, and scanned on NanoZoomer SQ. QuPath V.3 was used for scoring and H-scores were assigned ranging from 0 to 300, considering staining intensity and percentage of positive cells. Details for the human patient tissues and animal tissues are described in Supplemental Table 1 and 2, respectively.</p></section><section id="Sec13"><h3 class="pmc_sec_title">In vitro cytotoxicity</h3>
<p id="Par75">A water-soluble tetrazolium salt assay (WST-8) (Abcam) or Cell Titer Glo assay (Promega) was used to determine cytotoxicity, following treatment with ADC, in vitro. Briefly, 2 × 10<sup>3</sup> or 5 × 10<sup>3</sup> target cells were cultured for 72 h with titrated ADC or titrated primary antibody plus ADC anti-Fc secondary antibody (Moradec, final concentration 0.2 ug/ml). After incubation Wst-8 reagent was added and cells were cultured for a further 3 h to allow colour to develop. Absorbance was then read at 450 nmol/L using a Tecan Infinate M Plex plate reader and cell survival was calculated compared to a medium only control well. If the Cell Titer Glo assay was used for calculation of cell survival, after 72 h incubation, Cell Titer Glo reagent was added 1:1 and placed on an orbital shaker for 2 min. The plate was further incubated for 10 min. Luminescence was then detected using a Tecan Infinite M Plex plate reader. Cell survival was calculated using the formula: A450/luminescence test wells ÷ A450/luminescence cell only control wells × 100. Linear regression was used to calculate EC<sub>50</sub> values (Graphpad Prism v10.2.3). For the bystander killing assay, 1 × 10<sup>3</sup> target negative AGS cells were co-cultured with increasing ratios of DMS79 cells, in the presence of SC134-deruxtecan, or Rituximab-Deruxtecan. After 6 days of culture, DMS79 cells were stained with SC134-AF647 and the AGS cell count/ml determined.</p></section><section id="Sec14"><h3 class="pmc_sec_title">In vitro antibody dependent cell cytotoxicity (ADCC)</h3>
<p id="Par76">Target DMS79 (20,000 cells) were co-cultured with or without effector PBMC at a ratio of 20:1 effector:target. PBMC were isolated from Leukopaks (BioIVT) through density gradient centrifugation. Ethics approval was obtained from the IRB (tracking number 20190318). All donors signed informed consent. The cells were cultured in the presence of SC134-deruxtecan or Rituximab-Deruxtecan, serially diluted to 100, 10, 1, 0.1, 0.01, and 0 nmol/L. After 12 h incubation, 50 µl of supernatant was taken for measurement of cell cytotoxicity via lactate dehydrogenase (LDH) release, using CytoTox 96 Non-radioactive cytotoxicity assay, according to the manufacturer’s recommendation (Promega). The percentage cytotoxicity of test wells with DMS79 and PBMC co-culture was determined with the formula: (experimental LDH release − effector spontaneous LDH release − target spontaneous LDH release)/(target maximum LDH release − target spontaneous LDH release) × 100. Percentage cytotoxicity of wells with DMS79 only were calculated using the formula: experimental LDH release/target maximum LDH release × 100.</p></section><section id="Sec15"><h3 class="pmc_sec_title">In vivo anti-tumour model</h3>
<p id="Par77">In vivo work was carried out by Crown Biosciences under home office project licence number PP1144128. Animal welfare for the study complied with the UK Animals Scientific Procedures Act 1986 (ASPA). BALB/c nude mice (Charles River, n = 10/group, total number of 30 mice) were inoculated with 2 × 10<sup>6</sup> DMS79 cells. Upon tumour growth to an average size of 100 mm<sup>3</sup>, mice were randomised into three groups and dosed intravenously with 3 mg/kg SC134-Deruxtecan, 3 mg/kg Rituximab-Deruxtecan, or vehicle (PBS, 10 ml/kg). Mice were dosed twice, two weeks apart, following the day of randomization. Body weight and tumour growth were measured biweekly until termination on day 39. A Two-way ANOVA Model with Geisser-Greenhouse correction (Graphpad Prism v10.2.3) was applied to tumour growth data to determine significant differences between groups. Last observation carried forward (LOCF) was used for the control group on day 37, as a result of loss of animals due to reaching the tumour volume endpoint.</p></section><section id="Sec16"><h3 class="pmc_sec_title">Statistical analyses</h3>
<p id="Par78">All statistical analyses were calculated using Graphpad Prism, version 10.2.3. Significant <em>P</em> values were taken as <em>P</em> ≤ 0.05.</p></section></section><section id="Sec17"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec18"><h3 class="pmc_sec_title">SC134 exhibits avid FucGM1 binding, facilitated by a narrow binding pocket</h3>
<p id="Par79">We previously reported the creation of a FucGM1-targeting monoclonal antibody (mAb) obtained via a complex Balb/c immunisation regimen [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. SC134, the humanised lead mAb, retained the original FucGM1 binding characteristics, binding FucGM1 glycolipid with a half maximal effective concentration (EC<sub>50</sub>) of 0.08 nmol/L on ELISA (Fig. <a href="#Fig1" class="usa-link">1</a>B). Additionally, SC134 also bound FucGM1-BSA (comprising the FucGM1 hexasaccharide headgroup grafted onto the BSA carrier) albeit with lower efficiency (EC<sub>50</sub>, 0.2 nmol/L). Critically, no meaningful cross-reactivity towards GM1 was detected, in spite of using an amplified (biotin-streptavidin) detection setup, suggesting the terminal <em>α</em>1-2 Fucose is crucial for binding specificity. This was further corroborated by SPR analysis, where SC134 exhibited a concentration-dependent response to FucGM1-BSA, but critically, showed no cross-reactivity towards GM1a-BSA (Fig. <a href="#Fig1" class="usa-link">1</a>C), confirming the ELISA results.</p>
<p id="Par80">In order to further understand the structural nature of the SC134-FucGM1 binding specificity, and the role of Fucose, we performed in silico modelling of SC134 combined with docking of the FucGM1 hexasaccharide. SC134 engaged FucGM1 (supplemental Fig. 1A) through a narrow binding pocket, with the terminal three glycans (Fucose (Fuc5), Galactose (Gal4) and N-acetyl galactosamine (NGA3) driving the interaction (Fig. <a href="#Fig1" class="usa-link">1</a>D and Supplemental Fig. 1B). FucGM1 binding to SC134 was largely mediated by residues in CDRH2, CDRH3, CDRL1 and CDRL3. Fuc5, residing in the centre of the binding pocket, made the majority of the interactions with SC134 through a combination of electrostatic interactions (PRO100, VAL101 and ARG102 in CDRH3) and hydrogen bonds with ASP151 and HIS153 (CDRL1). Additionally, GAL4 sitting on the rim of the binding pocket, interacted with CDRH3 GLU99 and formed H-bond with main chain GLY210. NGA3 provided support to both GAL4 and FUC5 by bridging between CDRH2 HIS53 and CDRL3 HIS211 with a bond distance of 3.1 Angstrom (Å) on either side, consequently forming H-bonds (Supplemental Fig. 1B). In contrast, galactose (GAL2) and sialic acid (SIA6), both being more solvent exposed, were further removed from the binding pocket, and BGC1 due to its membrane proximity was furthest removed. The model, whilst requiring experimental validation, indicates a crucial role for Fucose interactions stabilising the FucGM1 binding to SC134 thereby providing a potential explanation for the lack of GM1 cross-reactivity by SC134.</p></section><section id="Sec19"><h3 class="pmc_sec_title">FucGM1 exhibits a superb differential tumour versus normal tissue distribution and is expressed in preclinical toxicology models</h3>
<p id="Par81">High-level target expression in tumour tissues combined with restricted normal tissue distribution are critical attributes for ADC development. Due to the lipid nature of FucGM1, its expression can only be evaluated on fresh or frozen tissues. Historic analyses have demonstrated FucGM1 expression in 58–90% of SCLC tumours, with a much smaller fraction of NSCLC tissues (squamous as well as adenocarcinoma] being positive [<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>–<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>, <a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>]. We previously reported more than 80% positive FucGM1 expression in frozen SCLC patient-derived xenograft tissues (PDX) [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. Comparison of this FucGM1 expression profile with that of DLL3, an alternative clinically validated SCLC target, indicated increased FucGM1 expression compared to DLL3 in eleven out of thirteen tissues (Fig. <a href="#Fig2" class="usa-link">2</a>A). We expanded on these PDX tissues by analysing commercially sourced frozen SCLC patient tissues (Supplemental Table 1). Robust FucGM1 target expression was evident in all five examined SCLC tissues, with H-scores up to 102 (Fig. <a href="#Fig2" class="usa-link">2</a>B). DLL3 expression was again lower than FucGM1. Thyroid Transcription Factor 1 (TTF-1), a marker for primary lung tumours was widely expressed in all patient tissues, with the strongest expression coinciding with the stronger FucGM1 expression. Across a frozen NSCLC array comprising adenocarcinoma as well as squamous carcinoma tissues, FucGM1 expression was evident in five out of twenty squamous NSCLC, with four tissues displaying a H-score between 5 and 150. SC134 displayed an excellent normal tissue distribution with previously reported low-level expression in only three normal human tissues: skin, pituitary and thymus [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. The absence of meaningful GM1 cross-reactivity was evident from the fact that neither frozen neuronal tissues such as cerebellum, cerebrum [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>] nor full-face peripheral nerve exhibited staining for FucGM1 (Supplemental Fig. 3B).</p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366213_12967_2025_6940_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1cf/12366213/760d55b94c7b/12967_2025_6940_Fig2_HTML.jpg" loading="lazy" id="MO2" height="987" width="724" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>FucGM1 exhibits a superb differential tumour versus normal tissue distribution and is expressed in preclinical toxicology models <strong>A</strong> Comparative H-scores for DLL3 expression by PDX tissues (Supplemental Fig. <a href="#Fig3" class="usa-link">3</a>A) compared to FucGM1 from [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]; <strong>B</strong> Comparative H-scores and staining for FucGM1, DLL3 and TTF-1 in patient SCLC samples (patient details in Supplemental Table 1); <strong>C</strong> H-score distribution of FucGM1 in squamous NSCLC tissues (staining in Supplemental Fig. <a href="#Fig3" class="usa-link">3</a>C); <strong>D</strong> FucGM1 positive mouse tissues: (A) breast, (B) colon, (C) skeletal muscle, (D) pancreas, (E) skin, (F) small intestine (G) stomach (H) testes, (I) thymus, (J) Pituitary (C57BL/6); <strong>E</strong> FucGM1 positive rat tissues (A) mesothelium, (B) stomach (foveolar cells), (C) stomach (crypt cells); <strong>F</strong> FucGM1 positive cynomolgous monkey tissues: (A) thymus, (B) skin and (C) small intestine</p></figcaption></figure><p id="Par82">The FucGM1 glycolipid is conserved across all animal species, however species-specific normal tissue distribution is evident, largely driven by the tissue-specific expression of the biosynthetic enzymes [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>, <a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>]. Normal mouse tissues, in contrast to humans, exhibited a wider FucGM1 expression, comprising ten FucGM1-positive tissues, three of which overlapped with human (skin, thymus and pituitary) (Fig. <a href="#Fig2" class="usa-link">2</a>D). Strong FucGM1 expression was observed in stomach, with more moderate to weak expression in breast, colon, skeletal muscle, pancreas, skin, small intestine, testes, thymus, and pituitary. Rat showed a more restricted distribution with two positive tissues: mesothelium and stomach: foveolar and crypt cells, neither of which were seen in humans (Fig. <a href="#Fig2" class="usa-link">2</a>E). Frozen cynomolgus monkey tissues mimicked the restricted FucGM1 distribution seen in humans, with thymus and skin exhibiting weak FucGM1 staining (Fig. <a href="#Fig2" class="usa-link">2</a>F), but unlike the human tissues, cynomolgus small intestine was also weakly positive for FucGM1.</p></section><section id="Sec20"><h3 class="pmc_sec_title">SC134 targets SCLC cell lines with nanomolar efficiency and displays efficient internalization</h3>
<p id="Par83">SC134 binding of SCLC cell surface occurred with nanomolar efficiency (Fig. <a href="#Fig3" class="usa-link">3</a>A). DMS79, a high-FucGM1 expressing cell line, showed high binding efficiency (EC<sub>50</sub> 43 nmol/L), followed by DMS153 and DMS53 (EC<sub>50</sub> 171 nmol/L and 231 nmol/L, respectively), and somewhat lower efficiency on the low-expressing H526 (EC<sub>50</sub> 7.7 µmol/L). The binding histograms revealed a relatively broad distribution of SC134 binding on DMS53 and H526 (Fig. <a href="#Fig3" class="usa-link">3</a>A). Quantification of the antibody binding capacity (ABC) (at saturation), using the murine version of SC134, revealed DMS79 to have approximately 10<sup>6</sup> ABC units and DMS53 of the order of 10<sup>5</sup> ABC. DMS153 consistently showed ABC in the same order of magnitude as DMS79. H526 is estimated to have a lower ABC based on the binding data in Fig. <a href="#Fig3" class="usa-link">3</a>A.</p>
<figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366213_12967_2025_6940_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1cf/12366213/6dc29329b48f/12967_2025_6940_Fig3_HTML.jpg" loading="lazy" id="MO3" height="963" width="778" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>SC134 targets SCLC cell lines with nanomolar efficiency and displays efficient internalization <strong>A</strong> Flow cytometry analysis of SC134 cell binding to SCLC cell lines. Histograms show binding of 50 nM SC134 (DSM79, DMS53, H526) or 500 nM SC134 (DMS153) (black) against control (gray); <strong>B</strong> SC134 internalization on DMS79, anti-transferrin receptor antibody was included as a positive control; i. representative cellular fluorescence of AF647-SC134 or AF647-anti-transferrin receptor over time, out of approximately 500–1500 gated events. Image number corresponds to the recorded event acquisition number. Brightness is increased for transferrin receptor labelling compared to SC134 to help visualization of antibody location. This does not affect internalization values. ii. internalization score of each antibody over time. iii. Percentage of AF647-positive cells with a positive internalization score, over time. <strong>C</strong> Co-localization of SC134-AF647 (red) and lysosomal LAMP1 (green) following incubation of DMS79 cells in the presence of SC134-AF647 for 0 h (i) and 24 h (ii)</p></figcaption></figure><p id="Par84">A prerequisite for ADC functionality is cellular internalization and release of the cytotoxic drug via lysosomal proteases. Consequently, the SC134 internalization kinetics and lysosomal colocalization using DMS79 cells were investigated using AF647-conjugated SC134 and imaging flow cytometry (Fig. <a href="#Fig3" class="usa-link">3</a>B, C). Over the 48 h incubation period, progressive internalization of SC134 was observed (Fig. <a href="#Fig3" class="usa-link">3</a>Bi), with a calculated half-live of 6.9 h (Fig. <a href="#Fig3" class="usa-link">3</a>Bii). The percentage of cells with internal fluorescence gradually increased over time to a maximum of 55% at 48 h (Fig. <a href="#Fig3" class="usa-link">3</a>Biii). AF647-anti-transferrin receptor antibody showed faster internalization (internalization half-live of 3.4 h), with a positive internalization score from 1 h onwards, in line with its literature-reported fast internalization and lower surface expression levels [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>, <a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>]. SC134 showed increasing colocalization with the lysosome (based on lysosomal associated membrane protein 1 (LAMP1) colocalization) over time (Fig. <a href="#Fig3" class="usa-link">3</a>C, supplemental Fig. 4), with visible colocalization from 1 h (Supplemental Fig. 4), and reaching a maximum at 24 h, suggesting SC134 is successfully delivered to the lysosome following internalization.</p></section><section id="Sec21"><h3 class="pmc_sec_title">Indirect ADC screens reveal potent target-dependent killing of SCLC tumour cells by SC134 across a range of DNA-targeting drugs</h3>
<p id="Par85">The effective internalization of SC134 prompted its evaluation for cytotoxic drug delivery. Intracellular drug delivery was evaluated, initially, using Fab-based drug-conjugated anti-human Fc constructs (Moradec LLC). This allowed for the screening of drugs with a range DNA-targeting actions such as the duocarmycin (DMDM), pyrolobenzodiazepin (PBD), anthracylin (PNU) and TOP1i, exatecan mesylate (DX8951). Over the 72 h incubation period, impact on cell survival was evident with PBD being the most efficient at killing, with an EC<sub>50</sub> of 16 pmol/L, followed by DMDM (EC<sub>50</sub> 49 pmol/L), DX8951 (EC<sub>50</sub> 0.15 nmol/L) and PNU (EC<sub>50</sub> 0.42 nmol/L) (Supplemental Fig. 5A–D). The window for target-dependent impact of PNU was much reduced compared to the other drugs (Supplemental Fig. 5D). The most complete cell reduction was seen with the TOP1i, DX8951 (Supplemental Fig. 5C), reducing cell survival to 25%, informing the decision to create SC134-deruxtecan through covalent conjugation.</p></section><section id="Sec22"><h3 class="pmc_sec_title">SC134-deruxtecan shows potent in vitro SCLC cell killing with bystander and effector cell-mediated impact</h3>
<p id="Par86">SC134-deruxtecan, as well as a non-targeting control (Rituximab-deruxtecan) with peptidyl cleavable linker and an average DAR4 or DAR8 were created using interchain cysteine conjugation. SC134 binding to DMS79 was unaffected by conjugation to deruxtecan (Supplemental Fig. 5E). SC134-deruxtecan DAR8 showed somewhat improved killing efficiency (EC<sub>50</sub> 1.3 nmol/L) compared to DAR4 (EC<sub>50</sub> 5.6 nmol/L, Supplemental Fig. 5F), therefore this ADC was taken forward for further in vitro and in vivo studies. SC134-deruxtecan showed potent killing activity against the high FucGM1 expressing cell line DMS79 and DMS153 with nanomolar efficiency (EC<sub>50</sub> 1.7 and 14 nmol/L, respectively, Fig. <a href="#Fig4" class="usa-link">4</a>A). Killing was also seen against the moderate expressing cell line DMS53 with EC<sub>50</sub> 47.8 nmol/L, but little activity was seen against the low expressing H526 (Fig. <a href="#Fig4" class="usa-link">4</a>A). The target-dependent nature of the cell killing was evident from the lack of impact by the non-targeting Rituximab-deruxtecan as well as the negligible impact on the target-negative AGS (Supplemental Fig. 5G).</p>
<figure class="fig xbox font-sm" id="Fig4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366213_12967_2025_6940_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1cf/12366213/3fefad842652/12967_2025_6940_Fig4_HTML.jpg" loading="lazy" id="MO4" height="876" width="784" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>SC134-deruxtecan shows potent in vitro SCLC cell killing, with bystander and effector cell mediated impact <strong>A</strong> Cell survival assay, following 72 h culture with SC134 and non-targeting rituximab control ADC using DMS79, DMS153, DMS53 and H526. <strong>B</strong> Bystander assay showing AGS cell number following 6-day co-culture with increasing DMS79 ratios and ADC concentrations for 6 days. AGS cell number was determined through flow cytometry and negative gating with SC134-AF647. <strong>C</strong> ADCC activity measured as percentage cytotoxicity following co-culture of DMS79 target cells with PBMC in the presence of SC134-deruxtecan or rituximab-deruxtecan control. DMS79 alone with SC134-deruxtecan was used as a negative control for ADCC</p></figcaption></figure><p id="Par87">Bystander killing was examined through co-culture of target-positive DMS79 and target-negative AGS cells with SC134-deruxtecan or non-targeting Rituximab-deruxtecan (Fig. <a href="#Fig4" class="usa-link">4</a>B). AGS cell numbers decreased at 10 nmol/L SC134-deruxtecan, the efficiency of which correlating with increasing DMS79 cells numbers. Target-dependency of the bystander killing was confirmed by the absence of killing by Rituximab-deruxtecan. Further to direct and bystander killing, SC134-deruxtecan mediated target cell death via antibody dependent cell cytotoxicity (ADCC), through its intact Fc region, with nanomolar efficiency (EC<sub>50</sub> 0.7 nmol/L) and up to 40% cell death (Fig. <a href="#Fig4" class="usa-link">4</a>C). Cell killing was only evident in the presence of PBMC, indicating this is ADCC-mediated and not due to direct killing by the ADC.</p></section><section id="Sec23"><h3 class="pmc_sec_title">Excellent in vivo tumour control against DMS79 xenograft by SC134-deruxtecan</h3>
<p id="Par88">To assess in vivo efficacy, SC134-deruxtecan and the non-targeting Rituximab-deruxtecan control ADC were tested against DMS79 in BALB/c Nude mice. Mice were randomised at day 10 with an average tumour volume of 102 mm<sup>3</sup> and treated with 3 mg/kg ADC, once every two weeks for four weeks (Fig. <a href="#Fig5" class="usa-link">5</a>, supplemental Fig. 6). SC134-deruxtecan showed significant (<em>p</em> &lt; 0.0001) target-dependent tumour control/eradication, with 80% of the mice being tumour-free at the end of study. The non-targeting control Rituximab-deruxtecan had a marginal impact on tumour growth. SC134-deruxtecan treatment was well tolerated and had no impact on mouse bodyweight (Fig. <a href="#Fig5" class="usa-link">5</a>B).</p>
<figure class="fig xbox font-sm" id="Fig5"><h4 class="obj_head">Fig. 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366213_12967_2025_6940_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1cf/12366213/7cca4f9c4e63/12967_2025_6940_Fig5_HTML.jpg" loading="lazy" id="MO5" height="903" width="797" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Excellent in vivo tumour control against DMS79 xenograft by SC134-deruxtecan <strong>A</strong> Anti-tumour efficacy of SC134-deruxtecan against DMS79 xenograft. Mice (n = 10/group) were randomised on day 10 when tumour size was ~ 102 mm<sup>3</sup>. SC134-deruxtecan and rituximab-deruxtecan were dosed at 3 mg/kg on day 11 and 25. Symbols represent mean tumour volume + SEM. Mixed effects model with Geisser-Greenhouse correction used for statistical tests. ****<em>p</em> ≤ 0.0001. <strong>B</strong> Relative mean bodyweight over time, as a percentage of bodyweight at start of dosing (day 11), following dosage of SC134-deruxtecan and non-targeting Rituximab-deruxtecan control. Symbols represent mean bodyweight + SEM</p></figcaption></figure></section></section><section id="Sec24"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par89">SC134 exhibited excellent FucGM1 binding specificity, without GM1 cross-reactivity. The latter attribute is critical as GM1 is abundantly expressed in neuronal tissues [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. This suggests that the terminal <em>α</em>1-2 linked Fucose is essential for binding by SC134 and our in silico modelling unveils key interactions between FUC5 and residues within CDRH3 and CDRL1 in SC134, that require further experimental verification. These interactions are absent for GM1 (not containing the Fucose) and could provide a rational why SC134 did not cross-react with GM1, as seen on ELISA and SPR.</p>
<p id="Par90">The analysis of FucGM1 distribution in SCLC patient samples is challenging due to the need for frozen tissues, combined with the fact that SCLC is rarely resected. Notwithstanding, IHC analysis on frozen PDX tissues [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>], as well as five SCLC patient samples indicated robust expression of FucGM1, with occasional focal distribution, matching the literature-reported expression levels, as well as those from our model cell line DMS79, previously reported to have an H-score of between 97 and 147 [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. A subset of patient tumours had lower H-scores, however, we anticipate SC134-deruxtecan to still maintain success against these tumours, as evidenced from in vitro activity against moderate expressing cell lines such as DMS53. Limited in vitro effect was demonstrated against the low expressing cell line, H526, however, this could potentially be increased by extracellular cleavage of the SC134-deruxtecan in the tumour microenvironment, as has been shown for Enhertu [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>]. Conversely, the lack of impact on ultra-low expressing tissues may be advantageous in reducing potential off-tumour toxicity. On comparison with an alternative SCLC target, Delta-like ligand 3 (DLL3), FucGM1 expression levels were usually higher, in spite of methodological differences, as DLL3 expression via IHC is predominantly analysed on FFPE specimen. Additionally, IHC does not distinguish between cell surface-associated DLL3, compared to the abundant intracellular pool [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>, <a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>]. In the PDX cohort, the majority of cases expressed both targets, in concordance with DLL3 being associated with tumours of neuroendocrine origin [<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>], but some only expressed FucGM1, suggesting FucGM1 may not fully overlap with DLL3 expression. FucGM1 expression was also evident in a subset (~ 20%) of squamous NSCLC, as has been reported in the literature [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]. A limitation of our analysis is the small number of patient samples, a direct result of the fact that SCLC is rarely resected and the fact that frozen tissues are required for FucGM1 IHC analysis. PDX material has been used to address this limitation [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>].</p>
<p id="Par91">In humans FucGM1 is virtually absent from normal tissues, with only very low-level expression in skin, pituitary and thymus [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. Non-human primates match this restricted distribution with only three FucGM1 tissues, two of which overlapped with humans (skin and thymus). In contrast, rodents exhibited wider (mice) and differential (rats) FucGM1 distribution, in line with species-specific glycosyl transferase expression [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>, <a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>]. In mice, however, three out of ten positive tissues overlapped with humans, suggesting it could still be a relevant preclinical rodent toxicity model.</p>
<p id="Par92">Clinical validation of FucGM1 as a target for SCLC therapy stems from BMS-986012, a FucGM1 targeting antibody with improved effector function and currently in clinical development in combination with chemotherapy and checkpoint inhibitors, where it shows a modest improvement in OS and was well tolerated [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]. We previously validated the use of SC134 as a T cell redirecting bispecific for SCLC therapy [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. This paper examined the merits of FucGM1 as a target for ADC development. SC134 exhibited effective internalization as demonstrated by antibody imaging and delivery of cytotoxic payloads to FucGM1-positive SCLC cells. Internalization kinetics demonstrated an internalization half-life of 6.9 h, which is in line with Trastuzumab internalization on cells expressing similar levels of target [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>]. High target expressing cells show increased intracellular drug exposure combined with extracellular drug release (which could contribute to bystander killing), and are modelled to have faster degradation rates, compared to lower expressing cells, despite a slower internalization half-life [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>]. A half-life of 6.9 h could be considered a slow rate of internalization in comparison to for instance the transferrin receptor, however, studies have shown that slower internalization rates allows for better tumour penetration and in vivo efficacy [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>]. This could explain the excellent tumour control showed by SC134-deruxtecan in vivo. Other gangliosides, such as GM1 and GD3, have shown recycling to the membrane following antibody binding and internalization [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>, <a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>]. The current study, however, demonstrated colocalization of SC134 with LAMP1, a lysosomal marker, suggesting that SC134 is delivered to the lysosomes for degradation, a prerequisite for ADC functionality.</p>
<p id="Par93">Following internalization, SC134 delivered its payload intracellularly, either directly conjugated or indirectly through the use of drug-conjugated secondary constructs, thereby causing target cell death. This was further augmented by ADCC via the unmodified Fc region of SC134. Indirect conjugates based on DNA-targeting activity all exhibited impact on DMS79. The TOP1i DX8951, exatecan mesylate, exhibited nanomolar efficiency, consequently deruxtecan was selected for covalent conjugation using the cleavable peptidyl linker: glycine-glycine-phenylalanine-glycine, as used by Trastuzumab-deruxtecan (T-DXd) [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>]. Furthermore, this linker reduces hydrophobicity, allowing for an increased DAR of 8 [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>]. SC134-deruxtecan was highly efficacious against DMS79 cells, with nanomolar EC<sub>50</sub>. Efficacy correlated with FucGM1 expression levels across a range of SCLC cell lines without target-independent impact. DMS79 was selected as the model for in vivo testing, as IHC analysis demonstrated it to be relevant to the clinical tissues as well as the PDX models [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. Potent target-mediated DMS79 killing was also evident in vivo after two weekly 3 mg/kg dose, with no apparent toxicities, in spite of a number of FucGM1 positive mouse tissues. In vivo, solid tumours can often show an “edge effect” where antibodies bind at the tumour periphery or in the immediate vicinity of blood vessels and show reduced penetration due to target binding. The use of a less potent drug (e.g. deruxtecan) allows for higher doses to be used, to saturate binding sites at the tumour edge and allow improved penetration. Interestingly, in spite of FucGM1 expression in several normal mouse tissues, notably the gastrointestinal tract tissues such as stomach, small intestine and colon, SC134-deruxtecan was well tolerated with no impact on bodyweight, suggesting that the target may not be accessible from the circulation (e.g. the lumen of the stomach) or that FucGM1 expression levels and/or internalisation kinetics in other normal tissues is suboptimal for cytotoxicity. Testicular toxicity was avoided by using only female mice.</p>
<p id="Par94">SC134-deruxtecan exhibited ADCC capability. Maintaining a fully functional Fc region may allow for improved efficacy via effector function contributions, as well as having a beneficial impact on ADC half-live [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>], there is however, some evidence that this could also contribute to ADC-associated interstitial lung disease (ILD) [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>, <a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>]. Recent work suggests that one way by which ILD could occur is through Fc-mediated ADC uptake by alveolar macrophages, independent of target expression, however the precise mechanisms have not been fully explored. Indeed, ILD is observed across a range of targets, drugs and linker designs, suggesting it is a multi-factorial process. To diminish the risk of ILD via macrophage uptake, SC134-deruxtecan could be Fc-ablated prior to moving into the clinic.</p>
<p id="Par95">The current ADC landscape in SCLC comprises several targets, notably: DLL3, B7H3, SEZ6 and Trop2, the majority of which using TOP1i-based drugs [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>–<a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>], in spite of the earlier clinical failure of the DLL3-targeting Rovalpituzumab tesirine (Rova-T) [<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>]. FucGM1 has several advantages compared to the aforementioned targets including a very high tumour specificity with very few normal human tissues expressing FucGM1, conservation of the target across preclinical tox models and critically, high-level tumour expression and efficient internalization. Of note, M3554 targeting the glycosphingolipid GD2 is a TOP1i ADC in development for glioblastoma and sarcoma, further validating glycolipids as promising targets for targeted drug delivery [<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>].</p></section><section id="Sec25"><h2 class="pmc_sec_title">Conclusion</h2>
<p id="Par96">In summary, SC134-deruxtecan with its high specificity for FucGM1, a clinically relevant SCLC target, and its proficient in vitro and in vivo killing of SCLC, is a compelling candidate for clinical advancement. The combination of its direct target-mediated impact as well as its potential for bystander and immune effector cell mediated cytotoxicity likely all contributed to its potent in vivo tumour eradication, underscoring its potential for therapeutic benefit.</p></section><section id="Sec26"><h2 class="pmc_sec_title">Supplementary Information</h2>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12366213/bin/12967_2025_6940_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1.</a><sup> (16.1KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM2"><div class="media p"><div class="caption">
<a href="/articles/instance/12366213/bin/12967_2025_6940_MOESM2_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 2.</a><sup> (15.3KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM3"><div class="media p"><div class="caption">
<a href="/articles/instance/12366213/bin/12967_2025_6940_MOESM3_ESM.pptx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 3.</a><sup> (6.8MB, pptx) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>We would like to thank David Onion at the University of Nottingham Flow Cytometry Facility for his assistance in carrying out imaging flow cytometry work.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<dl class="def-list">
<dt>1L</dt>
<dd><p id="Par5">First line</p></dd>
<dt>2L</dt>
<dd><p id="Par6">Second line</p></dd>
<dt>ABC</dt>
<dd><p id="Par7">Antibody binding capacity</p></dd>
<dt>ADC</dt>
<dd><p id="Par8">Antibody drug conjugate</p></dd>
<dt>ADCC</dt>
<dd><p id="Par9">Antibody dependent cell cytotoxicity</p></dd>
<dt>AF</dt>
<dd><p id="Par10">AlexaFluor</p></dd>
<dt>B7H3</dt>
<dd><p id="Par11">B7 Homolog 3</p></dd>
<dt>BGC1</dt>
<dd><p id="Par12">Beta-D-Glucopyranose</p></dd>
<dt>BSA</dt>
<dd><p id="Par13">Bovine serum albumin</p></dd>
<dt>CDR</dt>
<dd><p id="Par14">Complementarity-determining region</p></dd>
<dt>DAR</dt>
<dd><p id="Par15">Drug-antibody ratio</p></dd>
<dt>DLL3</dt>
<dd><p id="Par16">Delta-like canonical Notch ligand 3</p></dd>
<dt>DMDM</dt>
<dd><p id="Par17">Duocarmycin</p></dd>
<dt>DNA</dt>
<dd><p id="Par18">Deoxyribonucleic acid</p></dd>
<dt>DX8951</dt>
<dd><p id="Par19">Exatecan mesylate</p></dd>
<dt>EC<sub>50</sub>
</dt>
<dd><p id="Par20">Half maximal effective concentration</p></dd>
<dt>ES-SCLC</dt>
<dd><p id="Par21">Extensive stage small cell lung cancer</p></dd>
<dt>Fc region</dt>
<dd><p id="Par22">Fragment crystallizable region</p></dd>
<dt>FBS</dt>
<dd><p id="Par23">Fetal bovine serum</p></dd>
<dt>FFPE</dt>
<dd><p id="Par24">Formalin fixed paraffin embedded</p></dd>
<dt>Fuc5</dt>
<dd><p id="Par25">Fucose 5</p></dd>
<dt>FucGM1</dt>
<dd><p id="Par26">Fucosyl GM1</p></dd>
<dt>GAL2</dt>
<dd><p id="Par27">Galactose 2</p></dd>
<dt>GAL4</dt>
<dd><p id="Par28">Galactose 4</p></dd>
<dt>H-bond</dt>
<dd><p id="Par29">Hydrogen bond</p></dd>
<dt>HRP</dt>
<dd><p id="Par30">Horseradish peroxidase</p></dd>
<dt>HSA</dt>
<dd><p id="Par31">Human serum albumin</p></dd>
<dt>IHC</dt>
<dd><p id="Par32">Immunohistochemistry</p></dd>
<dt>ILD</dt>
<dd><p id="Par33">Interstitial lung disease</p></dd>
<dt>LDH</dt>
<dd><p id="Par34">Lactate dehydrogenase</p></dd>
<dt>LS-SCLC</dt>
<dd><p id="Par35">Limited stage small cell lung cancer</p></dd>
<dt>mAb</dt>
<dd><p id="Par36">Monoclonal antibody</p></dd>
<dt>MCK</dt>
<dd><p id="Par37">Multi-cycle kinetics</p></dd>
<dt>MOA</dt>
<dd><p id="Par38">Mechinism of action</p></dd>
<dt>NGA3</dt>
<dd><p id="Par39">N-acetyl galactosamine 3</p></dd>
<dt>NK</dt>
<dd><p id="Par40">Natural killer</p></dd>
<dt>NSCLC</dt>
<dd><p id="Par41">Non-small cell lung cancer</p></dd>
<dt>OS</dt>
<dd><p id="Par42">Overall survival</p></dd>
<dt>PBD</dt>
<dd><p id="Par43">Pyrolobenzodiazepin</p></dd>
<dt>PBMC</dt>
<dd><p id="Par44">Peripheral blood mononuclear cells</p></dd>
<dt>PDL1</dt>
<dd><p id="Par45">Programmed death ligand 1</p></dd>
<dt>PDX</dt>
<dd><p id="Par46">Patient-derived xenograft</p></dd>
<dt>PNU</dt>
<dd><p id="Par47">Anthracylin</p></dd>
<dt>Rova-T</dt>
<dd><p id="Par48">Rovalpituzumab tesirine</p></dd>
<dt>RP-HPLC</dt>
<dd><p id="Par49">Reversed-phase high-performance liquid chromatography</p></dd>
<dt>SCLC</dt>
<dd><p id="Par50">Small cell lung cancer</p></dd>
<dt>SIA6</dt>
<dd><p id="Par51">Sialic acid 6</p></dd>
<dt>SOC</dt>
<dd><p id="Par52">Standard of care</p></dd>
<dt>SPR</dt>
<dd><p id="Par53">Surface plasmon resonance</p></dd>
<dt>TTF-1</dt>
<dd><p id="Par54">Thyroid transcription factor-1</p></dd>
<dt>SEZ6</dt>
<dd><p id="Par55">Seizure protein 6</p></dd>
<dt>SG</dt>
<dd><p id="Par56">Sacituzumab govitecan</p></dd>
<dt>TCB</dt>
<dd><p id="Par57">T cell bispecific</p></dd>
<dt>T-DXd</dt>
<dd><p id="Par58">Trastuzumab deruxtecan</p></dd>
<dt>TOP1i</dt>
<dd><p id="Par59">Topoisomerase 1 inhibitor</p></dd>
<dt>Trop-2</dt>
<dd><p id="Par60">Tumor-associated calcium signal transducer 2</p></dd>
<dt>Wst8</dt>
<dd><p id="Par61">Water-soluble tetrazolium salt assay</p></dd>
</dl></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>Bryony Heath: Formal analysis, investigation, methodology, writing–original draft, Bubacarr G. Kaira: Formal analysis, investigation, methodology. Dhruma Thakker: Formal analysis, methodology. Omar J. Mohammed: Formal analysis, methodology. Ruhul Choudhury: Formal analysis, methodology. Foram Dave: Formal analysis, methodology. Poonam Vaghela: Formal analysis, methodology. Elena Dubinina: Formal analysis, methodology. Tina Parsons: Resources, validation. Lindy Durrant: Conceptualization, supervision, funding acquisition, validation, writing–review. Mireille Vankemmelbeke: Conceptualization, supervision, validation, writing–original draft, writing–review and editing.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>Funding was provided by Scancell Holdings PLC.</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>The data that support the findings of this study are available upon reasonable request to the corresponding author.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Ethics approval and consent to participate</h3>
<p id="Par97">Animal studies complied with the UK Animals Scientific Procedures Act 1986 (ASPA) and were carried out in concordance with Crown Bioscience’s UK Guidelines and Standard Operating Procedures. Patient-derived tumor material was sourced from Crown Bioscience International and was acquired after approval by the IntegReview Ethical Review Board. Patient SCLC tissues were acquired through AccioBiobank, BioMedica CRO and Indivdumed GmbH, according to local institutional review board (IRB) approval and with Informed Consent (IC). Human leukocytes were obtained by BioIVT under IRB approved protocols. All donors signed IC forms.</p></section><section id="FPar2"><h3 class="pmc_sec_title">Consent for publication</h3>
<p id="Par98">Not applicable.</p></section><section id="FPar3"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par99">LD has ownership interest in a patent. LD is a director and shareholder in Scancell Ltd. All other authors are employees of Scancell Ltd.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher's Note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Basumallik N, Agarwal M. Small cell lung cancer. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2025, StatPearls Publishing LLC. 2025.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/29494065/" class="usa-link">PubMed</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51–65.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(20)30539-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33285097/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Goldman%20JW,%20Dvorkin%20M,%20Chen%20Y,%20Reinmuth%20N,%20Hotta%20K,%20Trukhin%20D,%20et%20al.%20Durvalumab,%20with%20or%20without%20tremelimumab,%20plus%20platinum%E2%80%93etoposide%20versus%20platinum%E2%80%93etoposide%20alone%20in%20first-line%20treatment%20of%20extensive-stage%20small-cell%20lung%20cancer%20(CASPIAN):%20updated%20results%20from%20a%20randomised,%20controlled,%20open-label,%20phase%203%20trial.%20Lancet%20Oncol.%202021;22(1):51%E2%80%9365." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–39.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(19)32222-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31590988/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Paz-Ares%20L,%20Dvorkin%20M,%20Chen%20Y,%20Reinmuth%20N,%20Hotta%20K,%20Trukhin%20D,%20et%20al.%20Durvalumab%20plus%20platinum%E2%80%93etoposide%20versus%20platinum%E2%80%93etoposide%20in%20first-line%20treatment%20of%20extensive-stage%20small-cell%20lung%20cancer%20(CASPIAN):%20a%20randomised,%20controlled,%20open-label,%20phase%203%20trial.%20Lancet.%202019;394(10212):1929%E2%80%9339." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(6):739–47.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(22)00224-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35576956/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20J,%20Zhou%20C,%20Yao%20W,%20Wang%20Q,%20Min%20X,%20Chen%20G,%20et%20al.%20Adebrelimab%20or%20placebo%20plus%20carboplatin%20and%20etoposide%20as%20first-line%20treatment%20for%20extensive-stage%20small-cell%20lung%20cancer%20(CAPSTONE-1):%20a%20multicentre,%20randomised,%20double-blind,%20placebo-controlled,%20phase%203%20trial.%20Lancet%20Oncol.%202022;23(6):739%E2%80%9347." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Meriggi F. Second-line treatment options for small-cell lung cancer: a light at the end of the tunnel. Cancers (Basel). 2024;16(2):255.
</cite> [<a href="https://doi.org/10.3390/cancers16020255" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10813888/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38254746/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Meriggi%20F.%20Second-line%20treatment%20options%20for%20small-cell%20lung%20cancer:%20a%20light%20at%20the%20end%20of%20the%20tunnel.%20Cancers%20(Basel).%202024;16(2):255." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Prinetti A, Loberto N, Chigorno V, Sonnino S. Glycosphingolipid behaviour in complex membranes. Biochim Biophys Acta. 2009;1788(1):184–93.
</cite> [<a href="https://doi.org/10.1016/j.bbamem.2008.09.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18835549/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Prinetti%20A,%20Loberto%20N,%20Chigorno%20V,%20Sonnino%20S.%20Glycosphingolipid%20behaviour%20in%20complex%20membranes.%20Biochim%20Biophys%20Acta.%202009;1788(1):184%E2%80%9393." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Regina Todeschini A, Hakomori SI. Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains. Biochim Biophys Acta. 2008;1780(3):421–33.
</cite> [<a href="https://doi.org/10.1016/j.bbagen.2007.10.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2312458/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17991443/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Regina%20Todeschini%20A,%20Hakomori%20SI.%20Functional%20role%20of%20glycosphingolipids%20and%20gangliosides%20in%20control%20of%20cell%20adhesion,%20motility,%20and%20growth,%20through%20glycosynaptic%20microdomains.%20Biochim%20Biophys%20Acta.%202008;1780(3):421%E2%80%9333." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Jin X, Yang GY. Pathophysiological roles and applications of glycosphingolipids in the diagnosis and treatment of cancer diseases. Prog Lipid Res. 2023;91:101241.
</cite> [<a href="https://doi.org/10.1016/j.plipres.2023.101241" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37524133/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jin%20X,%20Yang%20GY.%20Pathophysiological%20roles%20and%20applications%20of%20glycosphingolipids%20in%20the%20diagnosis%20and%20treatment%20of%20cancer%20diseases.%20Prog%20Lipid%20Res.%202023;91:101241." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Degroote S, Wolthoorn J, van Meer G. The cell biology of glycosphingolipids. Semin Cell Dev Biol. 2004;15(4):375–87. 10.1016/j.semcdb.2004.03.007.</cite> [<a href="https://doi.org/10.1016/j.semcdb.2004.03.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15207828/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Degroote%20S,%20Wolthoorn%20J,%20van%20Meer%20G.%20The%20cell%20biology%20of%20glycosphingolipids.%20Semin%20Cell%20Dev%20Biol.%202004;15(4):375%E2%80%9387.%2010.1016/j.semcdb.2004.03.007." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Soula M, Unlu G, Welch R, Chudnovskiy A, Uygur B, Shah V, et al. Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer. Nature. 2024;633(8029):451–8.
</cite> [<a href="https://doi.org/10.1038/s41586-024-07787-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11892728/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39112706/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Soula%20M,%20Unlu%20G,%20Welch%20R,%20Chudnovskiy%20A,%20Uygur%20B,%20Shah%20V,%20et%20al.%20Glycosphingolipid%20synthesis%20mediates%20immune%20evasion%20in%20KRAS-driven%20cancer.%20Nature.%202024;633(8029):451%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Drivsholm L, Vangsted A, Pallesen T, Hansen M, Dombernowsky P, Hirsch F, et al. Fucosyl-GM1 in small-cell lung cancer. a comparison with the tumour marker neuron-specific enolase. Ann Oncol. 1994;5(7):623–6.
</cite> [<a href="https://doi.org/10.1093/oxfordjournals.annonc.a058934" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7993838/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Drivsholm%20L,%20Vangsted%20A,%20Pallesen%20T,%20Hansen%20M,%20Dombernowsky%20P,%20Hirsch%20F,%20et%20al.%20Fucosyl-GM1%20in%20small-cell%20lung%20cancer.%20a%20comparison%20with%20the%20tumour%20marker%20neuron-specific%20enolase.%20Ann%20Oncol.%201994;5(7):623%E2%80%936." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Nilsson OBF, Holmgren J, Sörenson S, Svennerholm L, Yngvason F, Lindholm L. Detection of a ganglioside antigen associated with small cell lung carcinomas using monoclonal antibodies directed against fucosyl-GM1. Can Res. 1986;46(3):1403–7.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/3002616/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nilsson%20OBF,%20Holmgren%20J,%20S%C3%B6renson%20S,%20Svennerholm%20L,%20Yngvason%20F,%20Lindholm%20L.%20Detection%20of%20a%20ganglioside%20antigen%20associated%20with%20small%20cell%20lung%20carcinomas%20using%20monoclonal%20antibodies%20directed%20against%20fucosyl-GM1.%20Can%20Res.%201986;46(3):1403%E2%80%937." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Brezicka FT, Olling S, Nilsson O, Bergh J, Holmgren J, Sörenson S, et al. Immunohistological detection of fucosyl-GM1 ganglioside in human lung cancer and normal tissues with monoclonal antibodies. Cancer Res. 1989;49(5):1300–5.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/2645049/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Brezicka%20FT,%20Olling%20S,%20Nilsson%20O,%20Bergh%20J,%20Holmgren%20J,%20S%C3%B6renson%20S,%20et%20al.%20Immunohistological%20detection%20of%20fucosyl-GM1%20ganglioside%20in%20human%20lung%20cancer%20and%20normal%20tissues%20with%20monoclonal%20antibodies.%20Cancer%20Res.%201989;49(5):1300%E2%80%935." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Daniotti JL, Vilcaes AA, Torres Demichelis V, Ruggiero FM, Rodriguez-Walker M. Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approaches. Front Oncol. 2013. 10.3389/fonc.2013.00306.
</cite> [<a href="https://doi.org/10.3389/fonc.2013.00306" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3867695/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24392350/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Daniotti%20JL,%20Vilcaes%20AA,%20Torres%20Demichelis%20V,%20Ruggiero%20FM,%20Rodriguez-Walker%20M.%20Glycosylation%20of%20glycolipids%20in%20cancer:%20basis%20for%20development%20of%20novel%20therapeutic%20approaches.%20Front%20Oncol.%202013.%2010.3389/fonc.2013.00306." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Sipione S, Monyror J, Galleguillos D, Steinberg N, Kadam V. Gangliosides in the brain: physiology, pathophysiology and therapeutic applications. Front Neurosci. 2020. 10.3389/fnins.2020.572965.
</cite> [<a href="https://doi.org/10.3389/fnins.2020.572965" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7574889/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33117120/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sipione%20S,%20Monyror%20J,%20Galleguillos%20D,%20Steinberg%20N,%20Kadam%20V.%20Gangliosides%20in%20the%20brain:%20physiology,%20pathophysiology%20and%20therapeutic%20applications.%20Front%20Neurosci.%202020.%2010.3389/fnins.2020.572965." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Iwamori M, Domino SE. Tissue-specific loss of fucosylated glycolipids in mice with targeted deletion of alpha(1,2)fucosyltransferase genes. Biochem J. 2004;380(1):75–81.
</cite> [<a href="https://doi.org/10.1042/BJ20031668" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1224153/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14967068/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Iwamori%20M,%20Domino%20SE.%20Tissue-specific%20loss%20of%20fucosylated%20glycolipids%20in%20mice%20with%20targeted%20deletion%20of%20alpha(1,2)fucosyltransferase%20genes.%20Biochem%20J.%202004;380(1):75%E2%80%9381." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Tokuda N, Zhang Q, Yoshida S, Kusunoki S, Urano T, Furukawa K. Genetic mechanisms for the synthesis of fucosyl GM1 in small cell lung cancer cell lines. Glycobiology. 2006;16(10):916–25.
</cite> [<a href="https://doi.org/10.1093/glycob/cwl022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16880505/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tokuda%20N,%20Zhang%20Q,%20Yoshida%20S,%20Kusunoki%20S,%20Urano%20T,%20Furukawa%20K.%20Genetic%20mechanisms%20for%20the%20synthesis%20of%20fucosyl%20GM1%20in%20small%20cell%20lung%20cancer%20cell%20lines.%20Glycobiology.%202006;16(10):916%E2%80%9325." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Chen S, Hayoun-Neeman D, Nagar M, Pinyan S, Hadad L, Yaacobov L, et al. Terminal alpha1,2-fucosylation of glycosphingolipids by FUT1 is a key regulator in early cell-fate decisions. EMBO Rep. 2024;25(10):4433–64.
</cite> [<a href="https://doi.org/10.1038/s44319-024-00243-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11467398/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39256596/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20S,%20Hayoun-Neeman%20D,%20Nagar%20M,%20Pinyan%20S,%20Hadad%20L,%20Yaacobov%20L,%20et%20al.%20Terminal%20alpha1,2-fucosylation%20of%20glycosphingolipids%20by%20FUT1%20is%20a%20key%20regulator%20in%20early%20cell-fate%20decisions.%20EMBO%20Rep.%202024;25(10):4433%E2%80%9364." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Dickler MN, Ragupathi G, Liu NX, Musselli C, Martino DJ, Miller VA, et al. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin Cancer Res. 1999;5(10):2773–9.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/10537341/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dickler%20MN,%20Ragupathi%20G,%20Liu%20NX,%20Musselli%20C,%20Martino%20DJ,%20Miller%20VA,%20et%20al.%20Immunogenicity%20of%20a%20fucosyl-GM1-keyhole%20limpet%20hemocyanin%20conjugate%20vaccine%20in%20patients%20with%20small%20cell%20lung%20cancer.%20Clin%20Cancer%20Res.%201999;5(10):2773%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Chu Q, Leighl NB, Surmont V, van Herpen C, Sibille A, Markman B, et al. BMS-986012, an anti-fucosyl-GM1 monoclonal antibody as monotherapy or in combination with Nivolumab in relapsed/refractory SCLC: results from a first-in-human phase 1/2 study. JTO Clin Res Rep. 2022;3(11):100400.
</cite> [<a href="https://doi.org/10.1016/j.jtocrr.2022.100400" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9579497/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36275912/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chu%20Q,%20Leighl%20NB,%20Surmont%20V,%20van%20Herpen%20C,%20Sibille%20A,%20Markman%20B,%20et%20al.%20BMS-986012,%20an%20anti-fucosyl-GM1%20monoclonal%20antibody%20as%20monotherapy%20or%20in%20combination%20with%20Nivolumab%20in%20relapsed/refractory%20SCLC:%20results%20from%20a%20first-in-human%20phase%201/2%20study.%20JTO%20Clin%20Res%20Rep.%202022;3(11):100400." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Kalinka E, Bahce I, Navarro Mendivil AF, Ready N, Chu QSC, Sugawara S, et al. 1786O BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): interim analysis (IA) of a randomized phase II study. Ann Oncol. 2024;35:S1061–2.</cite> [<a href="https://scholar.google.com/scholar_lookup?Kalinka%20E,%20Bahce%20I,%20Navarro%20Mendivil%20AF,%20Ready%20N,%20Chu%20QSC,%20Sugawara%20S,%20et%20al.%201786O%20BMS-986012%20(anti-fucosyl-monosialoganglioside-1%20%5Bfuc-GM1%5D)%20with%20carboplatin%20+%20etoposide%20+%20nivolumab%20(CE/NIVO)%20as%20first-line%20(1L)%20therapy%20in%20extensive-stage%20small%20cell%20lung%20cancer%20(ES-SCLC):%20interim%20analysis%20(IA)%20of%20a%20randomized%20phase%20II%20study.%20Ann%20Oncol.%202024;35:S1061%E2%80%932." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Dave F, Vaghela P, Heath B, Dunster Z, Dubinina E, Thakker D, et al. SC134-TCB targeting Fucosyl-GM1, a T cell-engaging antibody with potent antitumor activity in preclinical small cell lung cancer models. Mol Cancer Ther. 2024;23(11):1626–38.
</cite> [<a href="https://doi.org/10.1158/1535-7163.MCT-24-0187" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11532774/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39186309/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dave%20F,%20Vaghela%20P,%20Heath%20B,%20Dunster%20Z,%20Dubinina%20E,%20Thakker%20D,%20et%20al.%20SC134-TCB%20targeting%20Fucosyl-GM1,%20a%20T%20cell-engaging%20antibody%20with%20potent%20antitumor%20activity%20in%20preclinical%20small%20cell%20lung%20cancer%20models.%20Mol%20Cancer%20Ther.%202024;23(11):1626%E2%80%9338." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Powell HR, Islam SA, David A, Sternberg MJE. Phyre2.2: a community resource for template-based protein structure prediction. J Mol Biol. 2025. 10.1016/j.jmb.2025.168960.
</cite> [<a href="https://doi.org/10.1016/j.jmb.2025.168960" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7617537/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40133783/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Powell%20HR,%20Islam%20SA,%20David%20A,%20Sternberg%20MJE.%20Phyre2.2:%20a%20community%20resource%20for%20template-based%20protein%20structure%20prediction.%20J%20Mol%20Biol.%202025.%2010.1016/j.jmb.2025.168960." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Ponath P, Menezes D, Pan C, Chen B, Oyasu M, Strachan D, et al. A novel, fully human anti–fucosyl-GM1 antibody demonstrates potent in vitro and in vivo antitumor activity in preclinical models of small cell lung cancer. Clin Cancer Res. 2018;24(20):5178–89.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-18-0018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6499931/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30021910/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ponath%20P,%20Menezes%20D,%20Pan%20C,%20Chen%20B,%20Oyasu%20M,%20Strachan%20D,%20et%20al.%20A%20novel,%20fully%20human%20anti%E2%80%93fucosyl-GM1%20antibody%20demonstrates%20potent%20in%20vitro%20and%20in%20vivo%20antitumor%20activity%20in%20preclinical%20models%20of%20small%20cell%20lung%20cancer.%20Clin%20Cancer%20Res.%202018;24(20):5178%E2%80%9389." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Domino SE, Zhang L, Lowe JB. Molecular cloning, genomic mapping, and expression of two secretor blood group alpha (1,2)fucosyltransferase genes differentially regulated in mouse uterine epithelium and gastrointestinal tract. J Biol Chem. 2001;276(26):23748–56.
</cite> [<a href="https://doi.org/10.1074/jbc.M100735200" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11323419/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Domino%20SE,%20Zhang%20L,%20Lowe%20JB.%20Molecular%20cloning,%20genomic%20mapping,%20and%20expression%20of%20two%20secretor%20blood%20group%20alpha%20(1,2)fucosyltransferase%20genes%20differentially%20regulated%20in%20mouse%20uterine%20epithelium%20and%20gastrointestinal%20tract.%20J%20Biol%20Chem.%202001;276(26):23748%E2%80%9356." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Ciechanover A, Schwartz AL, Dautry-Varsat A, Lodish HF. Kinetics of internalization and recycling of transferrin and the transferrin receptor in a human hepatoma cell line. Effect of lysosomotropic agents. J Biol Chem. 1983;258(16):9681–9.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/6309781/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ciechanover%20A,%20Schwartz%20AL,%20Dautry-Varsat%20A,%20Lodish%20HF.%20Kinetics%20of%20internalization%20and%20recycling%20of%20transferrin%20and%20the%20transferrin%20receptor%20in%20a%20human%20hepatoma%20cell%20line.%20Effect%20of%20lysosomotropic%20agents.%20J%20Biol%20Chem.%201983;258(16):9681%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Sharma S, Li Z, Bussing D, Shah DK. Evaluation of quantitative relationship between target expression and antibody-drug conjugate exposure inside cancer cells. Drug Metab Dispos. 2020;48(5):368–77.
</cite> [<a href="https://doi.org/10.1124/dmd.119.089276" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7153564/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32086295/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sharma%20S,%20Li%20Z,%20Bussing%20D,%20Shah%20DK.%20Evaluation%20of%20quantitative%20relationship%20between%20target%20expression%20and%20antibody-drug%20conjugate%20exposure%20inside%20cancer%20cells.%20Drug%20Metab%20Dispos.%202020;48(5):368%E2%80%9377." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Guo Z. Ganglioside GM1 and the central nervous system. Int J Mol Sci. 2023. 10.3390/ijms24119558.
</cite> [<a href="https://doi.org/10.3390/ijms24119558" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10253378/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37298512/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Guo%20Z.%20Ganglioside%20GM1%20and%20the%20central%20nervous%20system.%20Int%20J%20Mol%20Sci.%202023.%2010.3390/ijms24119558." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Tsao L-C, Wang JS, Ma X, Sodhi S, Ragusa JV, Liu B, et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat Commun. 2025;16(1):3167.
</cite> [<a href="https://doi.org/10.1038/s41467-025-58266-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11965298/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40175391/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tsao%20L-C,%20Wang%20JS,%20Ma%20X,%20Sodhi%20S,%20Ragusa%20JV,%20Liu%20B,%20et%20al.%20Effective%20extracellular%20payload%20release%20and%20immunomodulatory%20interactions%20govern%20the%20therapeutic%20effect%20of%20trastuzumab%20deruxtecan%20(T-DXd).%20Nat%20Commun.%202025;16(1):3167." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Furuta M, Sakakibara-Konishi J, Kikuchi H, Yokouchi H, Nishihara H, Minemura H, et al. Analysis of DLL3 and ASCL1 in surgically resected small cell lung cancer (HOT1702). Oncologist. 2019;24(11):e1172–9.
</cite> [<a href="https://doi.org/10.1634/theoncologist.2018-0676" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6853124/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31068386/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Furuta%20M,%20Sakakibara-Konishi%20J,%20Kikuchi%20H,%20Yokouchi%20H,%20Nishihara%20H,%20Minemura%20H,%20et%20al.%20Analysis%20of%20DLL3%20and%20ASCL1%20in%20surgically%20resected%20small%20cell%20lung%20cancer%20(HOT1702).%20Oncologist.%202019;24(11):e1172%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Tanaka K, Isse K, Fujihira T, Takenoyama M, Saunders L, Bheddah S, et al. Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer. Lung Cancer. 2018;115:116–20.
</cite> [<a href="https://doi.org/10.1016/j.lungcan.2017.11.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29290251/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tanaka%20K,%20Isse%20K,%20Fujihira%20T,%20Takenoyama%20M,%20Saunders%20L,%20Bheddah%20S,%20et%20al.%20Prevalence%20of%20Delta-like%20protein%203%20expression%20in%20patients%20with%20small%20cell%20lung%20cancer.%20Lung%20Cancer.%202018;115:116%E2%80%9320." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Peddio A, Pietroluongo E, Lamia MR, Luciano A, Caltavituro A, Buonaiuto R, et al. DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: a narrative review. Crit Rev Oncol Hematol. 2024;204:104524.
</cite> [<a href="https://doi.org/10.1016/j.critrevonc.2024.104524" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39326646/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Peddio%20A,%20Pietroluongo%20E,%20Lamia%20MR,%20Luciano%20A,%20Caltavituro%20A,%20Buonaiuto%20R,%20et%20al.%20DLL3%20as%20a%20potential%20diagnostic%20and%20therapeutic%20target%20in%20neuroendocrine%20neoplasms:%20a%20narrative%20review.%20Crit%20Rev%20Oncol%20Hematol.%202024;204:104524." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Brezicka FT, Olling S, Bergman B, Berggren H, Engström CP, Hammarström S, et al. Coexpression of ganglioside antigen Fuc-GM1, neural-cell adhesion molecule, carcinoembryonic antigen, and carbohydrate tumor-associated antigen CA 50 in lung cancer. Tumour Biol. 1992;13(5–6):308–15.
</cite> [<a href="https://doi.org/10.1159/000217780" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1337798/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Brezicka%20FT,%20Olling%20S,%20Bergman%20B,%20Berggren%20H,%20Engstr%C3%B6m%20CP,%20Hammarstr%C3%B6m%20S,%20et%20al.%20Coexpression%20of%20ganglioside%20antigen%20Fuc-GM1,%20neural-cell%20adhesion%20molecule,%20carcinoembryonic%20antigen,%20and%20carbohydrate%20tumor-associated%20antigen%20CA%2050%20in%20lung%20cancer.%20Tumour%20Biol.%201992;13(5%E2%80%936):308%E2%80%9315." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Nessler I, Khera E, Vance S, Kopp A, Qiu Q, Keating TA, et al. Increased tumor penetration of single-domain antibody-drug conjugates improves in vivo efficacy in prostate cancer models. Cancer Res. 2020;80(6):1268–78.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-19-2295" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7073300/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31941698/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nessler%20I,%20Khera%20E,%20Vance%20S,%20Kopp%20A,%20Qiu%20Q,%20Keating%20TA,%20et%20al.%20Increased%20tumor%20penetration%20of%20single-domain%20antibody-drug%20conjugates%20improves%20in%20vivo%20efficacy%20in%20prostate%20cancer%20models.%20Cancer%20Res.%202020;80(6):1268%E2%80%9378." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Iglesias-Bartolome R, Crespo PM, Gomez GA, Daniotti JL. The antibody to GD3 ganglioside, R24, is rapidly endocytosed and recycled to the plasma membrane via the endocytic recycling compartment. Inhibitory effect of brefeldin A and monensin. FEBS J. 2006;273(8):1744–58.
</cite> [<a href="https://doi.org/10.1111/j.1742-4658.2006.05194.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16623710/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Iglesias-Bartolome%20R,%20Crespo%20PM,%20Gomez%20GA,%20Daniotti%20JL.%20The%20antibody%20to%20GD3%20ganglioside,%20R24,%20is%20rapidly%20endocytosed%20and%20recycled%20to%20the%20plasma%20membrane%20via%20the%20endocytic%20recycling%20compartment.%20Inhibitory%20effect%20of%20brefeldin%20A%20and%20monensin.%20FEBS%20J.%202006;273(8):1744%E2%80%9358." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>Iglesias-Bartolomé R, Trenchi A, Comín R, Moyano AL, Nores GA, Daniotti JL. Differential endocytic trafficking of neuropathy: associated antibodies to GM1 ganglioside and cholera toxin in epithelial and neural cells. Biochim Biophys Acta Biomembr. 2009;1788(12):2526–40.</cite> [<a href="https://doi.org/10.1016/j.bbamem.2009.09.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19800863/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Iglesias-Bartolom%C3%A9%20R,%20Trenchi%20A,%20Com%C3%ADn%20R,%20Moyano%20AL,%20Nores%20GA,%20Daniotti%20JL.%20Differential%20endocytic%20trafficking%20of%20neuropathy:%20associated%20antibodies%20to%20GM1%20ganglioside%20and%20cholera%20toxin%20in%20epithelial%20and%20neural%20cells.%20Biochim%20Biophys%20Acta%20Biomembr.%202009;1788(12):2526%E2%80%9340." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419–30.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2004413" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32469182/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shitara%20K,%20Bang%20YJ,%20Iwasa%20S,%20Sugimoto%20N,%20Ryu%20MH,%20Sakai%20D,%20et%20al.%20Trastuzumab%20deruxtecan%20in%20previously%20treated%20HER2-positive%20gastric%20cancer.%20N%20Engl%20J%20Med.%202020;382(25):2419%E2%80%9330." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097–108.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-15-2822" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27026201/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ogitani%20Y,%20Aida%20T,%20Hagihara%20K,%20Yamaguchi%20J,%20Ishii%20C,%20Harada%20N,%20et%20al.%20DS-8201a,%20a%20novel%20HER2-targeting%20ADC%20with%20a%20novel%20DNA%20topoisomerase%20I%20inhibitor,%20demonstrates%20a%20promising%20antitumor%20efficacy%20with%20differentiation%20from%20T-DM1.%20Clin%20Cancer%20Res.%202016;22(20):5097%E2%80%93108." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715–25.
</cite> [<a href="https://doi.org/10.1038/nri2155" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17703228/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Roopenian%20DC,%20Akilesh%20S.%20FcRn:%20the%20neonatal%20Fc%20receptor%20comes%20of%20age.%20Nat%20Rev%20Immunol.%202007;7(9):715%E2%80%9325." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Koganemaru S, Fuchigami H, Morizono C, Shinohara H, Kuboki Y, Furuuchi K, et al. Potential mechanisms of interstitial lung disease induced by antibody-drug conjugates based on quantitative analysis of drug distribution. Mol Cancer Ther. 2025;24(2):242–50.
</cite> [<a href="https://doi.org/10.1158/1535-7163.MCT-24-0267" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11791479/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39450538/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Koganemaru%20S,%20Fuchigami%20H,%20Morizono%20C,%20Shinohara%20H,%20Kuboki%20Y,%20Furuuchi%20K,%20et%20al.%20Potential%20mechanisms%20of%20interstitial%20lung%20disease%20induced%20by%20antibody-drug%20conjugates%20based%20on%20quantitative%20analysis%20of%20drug%20distribution.%20Mol%20Cancer%20Ther.%202025;24(2):242%E2%80%9350." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<span class="label">41.</span><cite>Shi J, Liu X, Wu L, Jiang Y, Zhang Y, Wang Y. Interstitial lung disease with antibody-drug conjugates: a real-world pharmacovigilance study based on the FAERS database during the period 2014–2023. Ther Adv Respir Dis. 2024;18:17534666241299936.
</cite> [<a href="https://doi.org/10.1177/17534666241299935" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11635890/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39660786/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shi%20J,%20Liu%20X,%20Wu%20L,%20Jiang%20Y,%20Zhang%20Y,%20Wang%20Y.%20Interstitial%20lung%20disease%20with%20antibody-drug%20conjugates:%20a%20real-world%20pharmacovigilance%20study%20based%20on%20the%20FAERS%20database%20during%20the%20period%202014%E2%80%932023.%20Ther%20Adv%20Respir%20Dis.%202024;18:17534666241299936." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR42">
<span class="label">42.</span><cite>Ajay A, Wang H, Rezvani A, Savari O, Grubb BJ, McColl KS, et al. Assessment of targets of antibody drug conjugates in SCLC. NPJ Precis Oncol. 2025;9(1): 1.
</cite> [<a href="https://doi.org/10.1038/s41698-024-00784-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11696236/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39748112/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ajay%20A,%20Wang%20H,%20Rezvani%20A,%20Savari%20O,%20Grubb%20BJ,%20McColl%20KS,%20et%20al.%20Assessment%20of%20targets%20of%20antibody%20drug%20conjugates%20in%20SCLC.%20NPJ%20Precis%20Oncol.%202025;9(1):%201." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR43">
<span class="label">43.</span><cite>Chandana SR, Choudhury NJ, Dowlati A, Chiang AC, Garmezy B, Kim J-H, et al. First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors. J Clin Oncol. 2024;42(16_suppl):3001.</cite> [<a href="https://scholar.google.com/scholar_lookup?Chandana%20SR,%20Choudhury%20NJ,%20Dowlati%20A,%20Chiang%20AC,%20Garmezy%20B,%20Kim%20J-H,%20et%20al.%20First-in-human%20study%20of%20ABBV-706,%20a%20seizure-related%20homolog%20protein%206%20(SEZ6)%E2%80%93targeting%20antibody-drug%20conjugate%20(ADC),%20in%20patients%20(pts)%20with%20advanced%20solid%20tumors.%20J%20Clin%20Oncol.%202024;42(16_suppl):3001." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR44">
<span class="label">44.</span><cite>Dowlati A, Chiang AC, Cervantes A, Babu S, Hamilton E, Wong SF, et al. Phase 2 open-label study of sacituzumab govitecan as second-line therapy in patients with extensive-stage SCLC: results from TROPiCS-03. J Thorac Oncol. 2025. 10.1016/j.jtho.2024.12.028.
</cite> [<a href="https://doi.org/10.1016/j.jtho.2024.12.028" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39755168/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dowlati%20A,%20Chiang%20AC,%20Cervantes%20A,%20Babu%20S,%20Hamilton%20E,%20Wong%20SF,%20et%20al.%20Phase%202%20open-label%20study%20of%20sacituzumab%20govitecan%20as%20second-line%20therapy%20in%20patients%20with%20extensive-stage%20SCLC:%20results%20from%20TROPiCS-03.%20J%20Thorac%20Oncol.%202025.%2010.1016/j.jtho.2024.12.028." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR45">
<span class="label">45.</span><cite>Guo Q, Gao B, Song R, Li W, Zhu S, Xie Q, et al. FZ-AD005, a novel DLL3-targeted antibody-drug conjugate with topoisomerase I inhibitor, shows potent antitumor activity in preclinical models. Mol Cancer Ther. 2024;23(10):1367–77.
</cite> [<a href="https://doi.org/10.1158/1535-7163.MCT-23-0701" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11443207/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38940283/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Guo%20Q,%20Gao%20B,%20Song%20R,%20Li%20W,%20Zhu%20S,%20Xie%20Q,%20et%20al.%20FZ-AD005,%20a%20novel%20DLL3-targeted%20antibody-drug%20conjugate%20with%20topoisomerase%20I%20inhibitor,%20shows%20potent%20antitumor%20activity%20in%20preclinical%20models.%20Mol%20Cancer%20Ther.%202024;23(10):1367%E2%80%9377." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR46">
<span class="label">46.</span><cite>Lin S, Zhang Y, Yao J, Yang J, Qiu Y, Zhu Z, et al. DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models. J Transl Med. 2024;22(1):766.
</cite> [<a href="https://doi.org/10.1186/s12967-024-05568-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11323672/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39143619/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lin%20S,%20Zhang%20Y,%20Yao%20J,%20Yang%20J,%20Qiu%20Y,%20Zhu%20Z,%20et%20al.%20DB-1314,%20a%20novel%20DLL3-targeting%20ADC%20with%20DNA%20topoisomerase%20I%20inhibitor,%20exhibits%20promising%20safety%20profile%20and%20therapeutic%20efficacy%20in%20preclinical%20small%20cell%20lung%20cancer%20models.%20J%20Transl%20Med.%202024;22(1):766." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR47">
<span class="label">47.</span><cite>Spira A, Dowlati A, Zhao J, Patel MR, Wang Q, Dong X, et al. 5 oral: preliminary results from a phase Ia/Ib, open-label, multicenter study of ZL-1310, a DLL3-targeted ADC, to evaluate the safety, tolerability, and pharmacokinetics in subjects with small cell lung cancer. Eur J Cancer. 2024. 10.1016/j.ejca.2024.114534.</cite> [<a href="https://scholar.google.com/scholar_lookup?Spira%20A,%20Dowlati%20A,%20Zhao%20J,%20Patel%20MR,%20Wang%20Q,%20Dong%20X,%20et%20al.%205%20oral:%20preliminary%20results%20from%20a%20phase%20Ia/Ib,%20open-label,%20multicenter%20study%20of%20ZL-1310,%20a%20DLL3-targeted%20ADC,%20to%20evaluate%20the%20safety,%20tolerability,%20and%20pharmacokinetics%20in%20subjects%20with%20small%20cell%20lung%20cancer.%20Eur%20J%20Cancer.%202024.%2010.1016/j.ejca.2024.114534." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR48">
<span class="label">48.</span><cite>Wang J, Duan J, Sun Y, Xing L, Han L, Wang Q, et al. ARTEMIS-001: data from a phase 1a/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC). J Clin Oncol. 2024;42(16_suppl):8093.</cite> [<a href="https://scholar.google.com/scholar_lookup?Wang%20J,%20Duan%20J,%20Sun%20Y,%20Xing%20L,%20Han%20L,%20Wang%20Q,%20et%20al.%20ARTEMIS-001:%20data%20from%20a%20phase%201a/b%20study%20of%20HS-20093%20in%20patients%20with%20relapsed%20small%20cell%20lung%20cancer%20(SCLC).%20J%20Clin%20Oncol.%202024;42(16_suppl):8093." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR49">
<span class="label">49.</span><cite>Wang J, Duan J, Xing L, Sun Y, Guo W, Wang H, et al. ARTEMIS-001: phase 1 study of HS-20093, a B7-H3-targeting antibody-drug conjugate, in patients with advanced solid tumor. J Clin Oncol. 2023;41(16_suppl):3017.</cite> [<a href="https://scholar.google.com/scholar_lookup?Wang%20J,%20Duan%20J,%20Xing%20L,%20Sun%20Y,%20Guo%20W,%20Wang%20H,%20et%20al.%20ARTEMIS-001:%20phase%201%20study%20of%20HS-20093,%20a%20B7-H3-targeting%20antibody-drug%20conjugate,%20in%20patients%20with%20advanced%20solid%20tumor.%20J%20Clin%20Oncol.%202023;41(16_suppl):3017." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR50">
<span class="label">50.</span><cite>Yamato M, Hasegawa J, Maejima T, Hattori C, Kumagai K, Watanabe A, et al. DS-7300a, a DNA topoisomerase I inhibitor, DXd-based antibody-drug conjugate targeting B7-H3, exerts potent antitumor activities in preclinical models. Mol Cancer Ther. 2022;21(4):635–46.
</cite> [<a href="https://doi.org/10.1158/1535-7163.MCT-21-0554" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9377751/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35149548/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yamato%20M,%20Hasegawa%20J,%20Maejima%20T,%20Hattori%20C,%20Kumagai%20K,%20Watanabe%20A,%20et%20al.%20DS-7300a,%20a%20DNA%20topoisomerase%20I%20inhibitor,%20DXd-based%20antibody-drug%20conjugate%20targeting%20B7-H3,%20exerts%20potent%20antitumor%20activities%20in%20preclinical%20models.%20Mol%20Cancer%20Ther.%202022;21(4):635%E2%80%9346." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR51">
<span class="label">51.</span><cite>Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18(1):42–51.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(16)30565-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5481162/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27932068/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rudin%20CM,%20Pietanza%20MC,%20Bauer%20TM,%20Ready%20N,%20Morgensztern%20D,%20Glisson%20BS,%20et%20al.%20Rovalpituzumab%20tesirine,%20a%20DLL3-targeted%20antibody-drug%20conjugate,%20in%20recurrent%20small-cell%20lung%20cancer:%20a%20first-in-human,%20first-in-class,%20open-label,%20phase%201%20study.%20Lancet%20Oncol.%202017;18(1):42%E2%80%9351." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR52">
<span class="label">52.</span><cite>Kalinovsky DV, Kibardin AV, Kholodenko IV, Svirshchevskaya EV, Doronin II, Konovalova MV, et al. Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors. J Immunother Cancer. 2022. 10.1136/jitc-2022-004646.
</cite> [<a href="https://doi.org/10.1136/jitc-2022-004646" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9240879/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35764367/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kalinovsky%20DV,%20Kibardin%20AV,%20Kholodenko%20IV,%20Svirshchevskaya%20EV,%20Doronin%20II,%20Konovalova%20MV,%20et%20al.%20Therapeutic%20efficacy%20of%20antibody-drug%20conjugates%20targeting%20GD2-positive%20tumors.%20J%20Immunother%20Cancer.%202022.%2010.1136/jitc-2022-004646." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12366213/bin/12967_2025_6940_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1.</a><sup> (16.1KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12366213/bin/12967_2025_6940_MOESM2_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 2.</a><sup> (15.3KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material3_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12366213/bin/12967_2025_6940_MOESM3_ESM.pptx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 3.</a><sup> (6.8MB, pptx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The data that support the findings of this study are available upon reasonable request to the corresponding author.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Journal of Translational Medicine are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s12967-025-06940-2"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/12967_2025_Article_6940.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.6 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12366213/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12366213/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12366213%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366213/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12366213/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12366213/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40830881/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12366213/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40830881/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12366213/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12366213/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="IIhXu2U22z3MCc5Qkhl4yFb7JcZXC1MWSxVeSPuF7OueJixHy5IdcfsDCilOf2NA">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
